In the second case-based discussion, Dr. Binod Dhakal and Dr. Prerna Mewawalla examine treatment considerations for an older patient with relapsed/refractory multiple myeloma (RRMM), multiple comorbidities, prior anti-CD38 exposure, and limited suitability for CAR T-cell therapy.
The conversation highlights the growing role of BCMA-directed bispecific antibodies for patients who may not be ideal candidates for cellular therapies due to age, comorbid conditions, logistical challenges, or treatment preferences.
Dr. Mewawalla discusses how fitness and overall clinical status often influence treatment decisions more than chronological age alone and emphasizes the importance of individualized patient assessment.
The discussion also explores the practical implementation of bispecific antibodies in academic and community settings, including the expansion of outpatient administration models and the importance of establishing workflows that support broader access to these therapies.
The segment underscores how increasing clinical experience and education may help facilitate the integration of bispecific antibodies across diverse practice settings for patients with RRMM.
